Imfinzi (durvalumab) is an immunotherapy cancer treatment used for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bile duct and gallbladder cancer, hepatocellular carcinoma, endometrial cancer, bladder cancer, and gastric and gastroesophageal junction cancers in certain patients.